256 related articles for article (PubMed ID: 29649806)
1. Rituximab in Refractory Chronic Spontaneous Urticaria: An Encouraging Therapeutic Approach.
Combalia A; Losno RA; Prieto-González S; Mascaró JM
Skin Pharmacol Physiol; 2018; 31(4):184-187. PubMed ID: 29649806
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience.
Rottem M; Segal R; Kivity S; Shamshines L; Graif Y; Shalit M; Kessel A; Panasoff J; Cohen S; Toubi E; Agmon-Levin N
Isr Med Assoc J; 2014 Aug; 16(8):487-90. PubMed ID: 25269339
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
Syrigos N; Grapsa D; Syrigou E
Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Kaplan AP; Giménez-Arnau AM; Saini SS
Allergy; 2017 Apr; 72(4):519-533. PubMed ID: 27861988
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
7. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
8. Treatment of severely recalcitrant chronic spontaneous urticaria: a discussion of relevant issues.
Wieder S; Maurer M; Lebwohl M
Am J Clin Dermatol; 2015 Feb; 16(1):19-26. PubMed ID: 25452254
[TBL] [Abstract][Full Text] [Related]
9. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
10. Use of omalizumab in the treatment of chronic urticaria.
Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
12. Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis.
Shaker M; Oppenheimer J; Wallace D; Lang DM; Rambasek T; Dykewicz M; Greenhawt M
J Allergy Clin Immunol Pract; 2020; 8(7):2360-2369.e1. PubMed ID: 31751758
[TBL] [Abstract][Full Text] [Related]
13. Current challenges and controversies in the management of chronic spontaneous urticaria.
Asero R; Pinter E; Marra AM; Tedeschi A; Cugno M; Marzano AV
Expert Rev Clin Immunol; 2015; 11(10):1073-82. PubMed ID: 26174347
[TBL] [Abstract][Full Text] [Related]
14. Autoreactive T cells in chronic spontaneous urticaria target the IgE Fc receptor Iα subunit.
Auyeung P; Mittag D; Hodgkin PD; Harrison LC
J Allergy Clin Immunol; 2016 Sep; 138(3):761-768.e4. PubMed ID: 27417022
[TBL] [Abstract][Full Text] [Related]
15. Treatment response to omalizumab in patients with refractory chronic spontaneous urticaria.
Syrigos N; Grapsa D; Zande M; Tziotou M; Syrigou E
Int J Dermatol; 2018 Apr; 57(4):417-422. PubMed ID: 29399789
[TBL] [Abstract][Full Text] [Related]
16. Detection of Low-Molecular-Weight Mast Cell-Activating Factors in Serum From Patients With Chronic Spontaneous Urticaria.
Cugno M; Tedeschi A; Frossi B; Bossi F; Marzano AV; Asero R
J Investig Allergol Clin Immunol; 2016; 26(5):310-313. PubMed ID: 27763857
[TBL] [Abstract][Full Text] [Related]
17. The maddening itch: an approach to chronic urticaria.
Viegas LP; Ferreira MB; Kaplan AP
J Investig Allergol Clin Immunol; 2014; 24(1):1-5. PubMed ID: 24765875
[TBL] [Abstract][Full Text] [Related]
18. Current and future therapies for treating chronic spontaneous urticaria.
Maurer M; Vena GA; Cassano N; Zuberbier T
Expert Opin Pharmacother; 2016 Jun; 17(8):1131-9. PubMed ID: 26918673
[TBL] [Abstract][Full Text] [Related]
19. Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
Ertaş R; Özyurt K; Yıldız S; Ulaş Y; Turasan A; Avcı A
Iran J Allergy Asthma Immunol; 2016 Feb; 15(1):82-6. PubMed ID: 26996116
[TBL] [Abstract][Full Text] [Related]
20. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience.
Ensina LF; Valle SO; Juliani AP; Galeane M; Vieira dos Santos R; Arruda LK; Melo JM; de Souza PK; Serpa FS; de Andrade DM; França AT; Campos RA; Camelo-Nunes I; Solé D
Int Arch Allergy Immunol; 2016; 169(2):121-4. PubMed ID: 27055122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
